TABLE 1.
Patient, brain metastases, and SRT characteristics
| Characteristic | Category | Value | |
|---|---|---|---|
| Patients (n = 147) | |||
| Age (years) | Median (range) | 66 | (22–85) |
| 22–65, n (%) | 70 | (47.6) | |
| >65, n (%) | 77 | (52.4) | |
| Sex, n (%) | Male | 73 | (49.7) |
| Female | 74 | (50.3) | |
| PS, n (%) | 0 | 95 | (64.6) |
| 1 | 35 | (23.8) | |
| 2 | 13 | (8.8) | |
| 3 | 4 | (2.7) | |
| Primary cancer, n (%) | Lung | 97 | (66.0) |
| Breast | 19 | (12.9) | |
| GI | 8 | (5.4) | |
| Kidney | 7 | (4.7) | |
| Melanoma | 5 | (3.4) | |
| Others | 11 | (7.5) | |
| Brain metastases (n = 250) and SRT | |||
| PTV prescription dose, n (%) | 20 Gy/1 fraction | 15 | (6.0) |
| 24 Gy/1 fraction | 90 | (36.0) | |
| 30 Gy/3 fractions | 48 | (19.2) | |
| 30 Gy/5 fractions | 3 | (1.2) | |
| 35 Gy/5 fractions | 94 | (37.6) | |
| GTV (cc) | Median (range) | 1.1 | (0.3–33.1) |
| 0.3–1, n (%) | 118 | (47.2) | |
| 1–4, n (%) | 95 | (38.0) | |
| >4, n (%) | 37 | (14.8) | |
| SRT modality, n (%) | Conformal RT | 12 | (4.8) |
| Manual VMAT | 103 | (41.2) | |
| HA VMAT | 135 | (54.0) | |
Abbreviations: GI, gastrointestinal; GTV, gross tumor volume; HA VMAT, HyperArc volumetric modulated arc therapy; PS, performance status; PTV, planning target volume; RT, radiotherapy; SRT, stereotactic radiotherapy.